CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Autor:	Sara Gori, Martina Ulivi, Gabriele Siciliano, Michele Papa, Irene Lombardo, Lucia Chico, Sonia Mazzucchi, Ciro De Luca, Letizia Curto, Filippo Baldacci
Přispěvatelé:	De Luca, C., Baldacci, F., Mazzucchi, S., Lombardo, I., Curto, L., Ulivi, M., Chico, L., Papa, M., Siciliano, G., Gori, S.
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	medicine.medical_specialty Medication‐overuse headache Calcitonin gene-related peptide medicine.disease_cause Article Internal medicine medicine oxidative stress resistant migraine CGRP Biomarkers Oxidative stress Resistant migraine Receptor business.industry biomarkers General Medicine Biomarker medicine.disease medication-overuse headache Allodynia Migraine Calcitonin Anxiety Biomarker (medicine) Medicine Oxidative stre medicine.symptom business
Zdroj:	Journal of Clinical Medicine Volume 10 Issue 19 Journal of Clinical Medicine, Vol 10, Iss 4586, p 4586 (2021)
ISSN:	2077-0383
DOI:	10.3390/jcm10194586
Popis:	Patients with high-frequency resistant migraine and medication-overuse headache are still the main clinical challenge in tertiary headache centers. The approval of targeted antibodies against the calcitonin gene-related peptide (CGRP) and its receptor represents a powerful instrument. In this study, we observed how biological and clinical features of resistant migraineurs responded to erenumab, fremanezumab, or galcanezumab. We found a reduction in advanced oxidation protein products (AOPP) as a biomarker of improved redox state after six months of treatment. We also found that treatment efficacy was precocious and maintained with high individual responder rates. In particular, seven out of ten patients achieved a reduction of 50% from the baseline at three months, which was maintained at six months, while about one out of our patients experienced a 75% reduction in headache frequency from the first month of treatment. The migraine disability assessment (MIDAS) and the associated fatigue, anxiety, and sleep quality also significantly improved. The allodynia symptom dropped from moderate/severe to mild/absent as a sign of central sensitization reduction. Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9564a9fc2cfa8a3e146621b50ee8d85 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.